Comparison of Triamcinolone With Pentoxifylline and Vitamin- E Efficacy in the Treatment of Stage 2 and 3 Oral Submucous Fibrosis

NCT ID: NCT05660694

Last Updated: 2022-12-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-01-01

Study Completion Date

2021-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To compare the efficacy of Triamcinolone with Pentoxifylline and Vitamin E in patients with stage two and three oral submucous fibrosis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To compare the efficacy of Triamcinolone with Pentoxifylline and Vitamin E in patients with stage two and three oral submucous fibrosis.

It was a randomized control clinical trial to compare efficacy of injection steroids versus pentoxifylline and vitamin E in the treatment of stage 2 and 3 OSF patient. Total 40 patients who presented with signs and symptoms of OSF were enrolled in our study that was evaluated over the period of (January 2020 to September 2021). Parameters taken in the study were age and mouth opening. Descriptive statistics and paired t-test were used for statistical analysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Triamcinolone Pentoxifylline Vitamin E Oral Submucosa Fibrosis Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Group 1: Triamcinolone Group 2: Pentoxifylline
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1: Triamcinolone

Injection steroid Triamcinolone 400mg with lidocaine 1:1 was given twice a week for 4 weeks in bi-lateral buccal mucosa in multiple sites

Group Type EXPERIMENTAL

Triamcinolone

Intervention Type DRUG

Comparison of Triamcinolone with Pentoxifylline and Vitamin- E Efficacy

Group 2: Pentoxifylline with Vitamin E

Pentoxifylline 40mg twice a day along with vitamin E supplement one tablet per day for 4 weeks

Group Type EXPERIMENTAL

Pentoxifylline with Vitamin E

Intervention Type DRUG

Comparison of Triamcinolone with Pentoxifylline and Vitamin- E Efficacy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Triamcinolone

Comparison of Triamcinolone with Pentoxifylline and Vitamin- E Efficacy

Intervention Type DRUG

Pentoxifylline with Vitamin E

Comparison of Triamcinolone with Pentoxifylline and Vitamin- E Efficacy

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with clinically diagnosed OSMF who have not undergone any treatment of OSMF in past
* Patients willing to quit their tobacco chewing habit, gutkha areca nut smoking
* Patients who are ready to attend regular follow-ups

Exclusion Criteria

* Patients who have undergone any treatment for OSF in past
* Patients with any evidence of cardiac, gastrointestinal, kidney, metabolic disorders, pregnant and lactating women's
* Patients with any co-existing disorder of the orofacial region other than OSF which may interfere with the study protocol
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Altamash Institute of Dental Medicine

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Abhishek Lal

Dr. Abhishek Lal

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Altamash Institute of Dental Medicine

Karachi, Sindh, Pakistan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Pakistan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Treatment of OSF stage 2 and 3

Identifier Type: -

Identifier Source: org_study_id